STAT3 promotes the proliferation and migration of hepatocellular carcinoma cells by regulating AKT2

Area of Science:

• Oncology
• Molecular Biology
• Hepatocellular Carcinoma Research

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern.
• The molecular mechanisms driving HCC progression require further elucidation.

Purpose of the Study:

• To investigate the correlation between Signal transducer and activator of transcription 3 (STAT3) and AKT signaling pathways in HCC.
• To determine the role of STAT3 and AKT2 in HCC cell proliferation, migration, and invasion.

Main Methods:

• In vitro transfection of HCC cells with si-STAT3 and si-AKT2.
• Quantitative reverse transcription PCR (RT-PCR) for mRNA expression.
• Western blot for protein expression.
• MTT and Transwell assays for cell proliferation, migration, and invasion.
• Chromatin immunoprecipitation (ChIP) and Dual-luciferase reporter (DLR) assays to analyze STAT3-AKT2 interaction.
• Nude mouse xenograft model for in vivo validation.

Main Results:

• STAT3 downregulation reduced phosphorylated AKT2 (p-AKT2) and downstream signaling in HCC cells.
• AKT2 downregulation decreased phosphorylated STAT3 (p-STAT3) and downstream signaling.
• STAT3 inhibition suppressed HCC cell proliferation, migration, and invasion, effects partially reversed by AKT2.
• STAT3 directly binds to the AKT2 promoter, and IL-6 enhances AKT2 promoter activity.
• In vivo studies confirmed STAT3 promotes tumor growth, with AKT2 modulating this effect.

Conclusions:

• STAT3 and AKT2 exhibit a mutual regulatory relationship in HCC.
• STAT3 promotes HCC occurrence and development by upregulating AKT2.
• Targeting the STAT3/AKT2 axis presents a potential therapeutic strategy for HCC.